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Background: Areca nut, the seed of fruit of an oriental palm, known as Areca catechu, is commonly chewed in
many countries. Diabetes, hypertension, cardiovascular diseases, oropharyngeal and oesophageal cancers have been
associated with areca nut chewing and the mechanism by which areca nut chewing increases the risk of systemic
diseases remains elusive. We hypothesize that systemic inflammation may be elevated among areca nut users,
which is linked with many systemic diseases. Therefore, this present study was conducted to examine the systemic
inflammation among areca nut chewers and healthy controls.
Methods: This was an observational cross sectional study carried out on areca nut chewers and healthy individuals
in Karachi, Pakistan. Participants were selected from a region of the city by invitation request sent from door to
door. Information was collected regarding the socio-demographic profile and the pattern of use, and a blood
sample was obtained to measure the level of C-reactive protein (CRP). We carried out multiple logistic regressions
to investigate the association between socio-demographic profile, areca nut chewing and CRP levels.
Results: We carried out final analysis on 1112 individuals of which 556 were areca nut chewers and 556 were the
age, gender and area matched controls. Areca nut chewers had a significantly higher proportion of men (15.1%,
n = 84) who had an elevated CRP (>10 mg/dl) as compared to controls (5.2%, n = 29). Multivariate analyses showed
that areca nut chewers had significantly higher odds of an elevated CRP (OR = 3.23, 95% CI 2.08-5.02, p value
<0.001) as compared to controls. Increase in amount of areca nut consumption had a significant dose–response
relationship with systemic inflammation (p for trend <0.001). Further analysis revealed that areca nut chewers with
tobacco additives were two times more likely to have an elevated CRP as compared to raw areca nut users. These
associations remained unchanged after adjustments for age, BMI and years of full time education.
Conclusions: Areca nut chewing has a significant association with systemic inflammation. Further work is required
to confirm that systemic inflammation is the main pathway by which areca nut use increases the risk of systemic
diseases.
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Areca nut is the seed of the fruit of a tropical palm tree,
Areca Catechu. This tree bears fruit throughout the year
and areca nut is obtained from it, which is a basic ingre-
dient of widely used chewing products [1]. Slices of
areca are used fresh or dried and occasionally cured be-
fore use by boiling, baking or roasting. These nuts are
chewed either in raw form or mixed with a variety of
substances including slaked lime (aqueous calcium hy-
droxide paste), artificial sweeteners, spices such as car-
damom, coconut, saffron and most significantly, these
nuts are also mixed with some tobacco products [2,3].
Areca nut is considered to be the fourth most com-
monly used psychoactive substance after tobacco, alco-
hol and caffeine and more than 10% of the World’s
population chew it regularly more commonly in Central,
Southern and South-east Asian countries [4]. Interest-
ingly, the number of areca chewers has remarkably
increased in Australia, United Kingdom, Europe and
USA especially among the immigrants settling in these
countries from the developing world [1]. Prevalence of
areca nut chewer varies in different regions of the world
with a higher prevalence in developing countries and
lower in the developed part of the world [1].
Substantial body of evidence now suggests that areca
nut chewing is associated with benign and malignant
diseases of the oral cavity. WHO International Agency
for Research on Cancer Monograph Working Group
(2009) highlighed that the evidence on areca nut and its
assosciation with oral, pharyngeal and esophageal cancer
is sufficient to establish a causal link [5]. Interestingly,
hepatocellular carcinoma, for which hepatitis B and C
infections are considered as major risk factors, has been
found commonly among areca nut chewers who were
free from hepatitis B/C infections [6]. There is also
growing evidence that areca nut chewing is associated
with many systemic diseases including obesity [7,8] dia-
betes mellitus [9,10], hypertension [10] and metabolic
syndrome [11]. Furthermore, areca nut chewing also
increases the risk of cardiovascular diseases and ultim-
ately increases all-cause mortality independent of trad-
itional risk factors of these conditions [12,13].
Although, evidence suggests that areca nut chewing
increases the risk of many systemic diseases, the under-
lying biological mechanisms of these associations remain
elusive and little has been known and published in this
area. There is compelling evidence that the alkaloids of
areca nut have a vital role in the initiation and progression
of oral and pharyngeal lesions by initiating local inflamma-
tion but there is no evidence as such that systemic inflam-
mation has some role in the development of systemic and
metabolic diseases among areca nut chewers. We hypothe-
size that systemic inflammation could be a main pathway
by which areca nut consumption increases the risks ofsystemic diseases. Therefore, the present study was con-
ducted to examine the systemic inflammation among areca
nut chewers in comparison to the general population.
Methods
Cohort selection
We included healthy individuals from population for this
study who were invited to outdoor patients department
of Civil Hospital Karachi, Pakistan. The details of areca
nut chewers and their selection have been described
elsewhere [14]. In brief, all willing healthy male indivi-
duals between the ages of 16 to 35 who visited the out-
door patient department during January 2009 to
December 2010 in response to the invitation were
included in this study. Apparently healthy men who
were chewers of areca products (i.e. Areca nut only or
Areca nut with tobacco additives) were included in this
study as cases. We prepared a list of 50 areca nut pro-
ducts commonly available in the market, so that indivi-
duals can be classified in groups accurately. Individuals
who visited the specially setup clinic in out patient de-
partment for participation in this study and had current
illness or wanted to had a follow up of a previous illness
were not included in this study. Individuals who refused
to participate in the survey or were unable to under-
stand Urdu (national language of Pakistan) were also
excluded from this survey.
Information about the basic demography and sub-
stance use was collected by using a questionnaire. This
was a 20-items questionnaire including the information
about socio-demographic profile (including age, years of
education, nature of job/study), pattern of substance use
(frequency, number of years of usage, daily consumption,
type of substance and family history of use). This ques-
tionnaire was assessed for comprehensiveness, relevance
and clarity by three health professionals. Based on their
comments and suggestions some items were modified
while five items were excluded. This was then piloted on
50 participants. The performance of the questionnaire
was assessed by validity and reliability analysis which
showed a fairly high validity and reliability with a Cron-
bach’s alpha for the studied sample as 0.90.
Men who responded to the invitation, who never
chewed areca products, smoked cigarettes or used any
other addictive substance were included in this study as
controls. Furthermore, potential participants from com-
munity were also approached by local political leaders
and key informants. Information about this particular
study was also conveyed in community in different social
gatherings to increase the community participation in
this study. Controls were selected based on age, gender
and area matched to cases. Any individual who came to
participate in the study and had a self-reported history
of any acute (acute febrile illnesses i.e. upper and lower
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chronic illness (e.g. hypertension, diabetes mellitus, arth-
ritis, asthma, COPD) were excluded from this study.
Participants were examined by a dentist at recruitment
site and those who had periodontal diseases were also
excluded from this study. An additional questionnaire
including the dietary as well as lifestyle habbits was also
filled by an interviewing physician or nurse. General
physical examination was conducted for all participants
including the anthropometric measurements following a
standard procedure of removing the shoes for height
and weight measurements. A single page information
sheet was designed to convey the aims and objectives of
the study to the participants and a verbal consent was
obtained prior to employing the questionnaire. A blood
sample was obtained to measure the level of circulating
C-reactive protein and other haematological profile of
the participants. All blood samples were collected in
serum-separating tubes containing anticoagulant in it.
These samples were then processed to a biochemistry la-
boratory where they were analysed for CRP using
Enzyme-linked immunosorbent assay (ELISA). The
Novex manufactured 96-well microplate reader and CRP
human ELISA kits were used for this analysis. This study
was approved by the hospital authorities and an inde-
pendent ethical committee also reviewed and approved
the study protocol.
Sample size estimation
We estimated the sample size to measure 6% difference
of dependency prevalence (assuming 20% prevalence of
systemic inflammation among areca users) between
groups at 0.05 significance level using two sided com-
parison and power of 80%. Sample size was computed
for both the X2 using the Yates’ continuity correction
and Fisher Exact test. A sample of 938 participants was
the minimum number required to be accrued to perform
this survey with an allocation ratio of 1.
Data analysis
We used Stata software version 11 (StataCorp, College
Station, TX, USA) to analyze the collected information.
Participants were divided into two groups according to
their substance consumption (“areca nut chewers” and
“controls”). Age was categorised into five years age bands
(age years 16–20,21-25,26-30 and 31–35) and education
into three categories <10 years, 10–12 years and
>12 years. Body mass index (BMI) was calculated from
weight (in kg) divided by height (in metres) squared and
categorised according to the World Health Organisation
(WHO) Asian population specific classification in which
BMI <18.5 is underweight, <23 is desirable, 23–27.5 is
overweight and >27.5 is classified as obese [15]. In our
sample only two individuals had BMI less than 18.5 so wecombined the underweight category with desirable group.
C-reactive protein was dichotomised; those who had a
CRP less than or equal to 10 mg/dl and CRP greater than
10, a cut off which has been consistently used in many
studies to assess the systemic inflammation [16,17]. We
used multiple logistic regression adding different explana-
tory variables to assess the association between areca nut
use and systemic inflammation. We also investigated the
interaction between different variables included in the
multivariate model.
Results
A total of 1112 men were included in this study, 556 areca
chewers and 556 healthy controls. Mean age of partici-
pants was 25.6± 5.6 years with no statistically significant
difference between cases and controls (p value= 0.73).
Mean BMI of the sample was 25.8 ± 4.0 kg/m2, no signifi-
cant difference was observed between cases and controls
(p value 0.17). Significant differences were observed in
years of full time education between cases and controls;
controls were significantly more likely to be less educated
as compared to cases (p value 0.001). Baseline distribution
of sample is summarized in Table 1.
The mean CRP level significantly differed (mean differ-
ence 2.59, p-value <0.01) between cases and controls with
higher level among cases (6.11 ± 3.8) compared with con-
trols (3.53± 3.6). The proportion of men who had an ele-
vated level of CRP (CRP >10 mg/dl) also significantly
differed between cases and controls, where 15.1% (n= 84)
areca nut chewers had an elevated CRP compared to 5.2%
(n= 29) controls. On logistic regression analysis, there was
no significant difference in likelihood of elevated CRP be-
tween age, BMI and education categories. However, areca
nut chewers had 3 times higher odds of having an elevated
CRP as compared to controls (OR 3.23, 95% CI 2.08-5.02,
p value< 0.001). This association remained significant and
slightly strengthened after adjusting for age, BMI and
years of education (Table 2).
The mean CRP level significantly differed (mean differ-
ence 1.89, p-value <0.01) between raw areca nut
chewers and areca nut chewers with tobacco additives
with higher level among areca nut chewers with tobacco
additives (7.18 ± 3.95) compared with raw areca nut
chewers (5.29 ± 3.44). The proportion of men with an
elevated CRP significantly differed between raw areca
nut chewers (12.1%, n = 38) and areca chewers with
tobacco additives (19.0%, n = 46). On sub-group analysis,
the controls were excluded from the analysis and likeli-
hood of elevated CRP was compared between raw areca
nut users and areca chewers with tobacco additives.
Men who used areca nut with tobacco additives were
two times more likely to have a higher CRP as compared
to raw areca nut users (OR 1.98, 95% CI 1.16-3.31, p
value 0.009) after adjusting for age, BMI and years of








Study participants (n) 1112 556 556
Age at screening, mean (SD) 1112 25.6 (5.6) 25.7 (5.6) 0.734
Age at screening (years) 0.641
Age 16-20 203 98 (17.6) 105 (18.9)
Age 21-25 425 211 (38.0) 214 (38.5)
Age 26-30 237 127 (22.8) 110 (19.8)
Age 31-35 247 120 (21.6) 127 (22.8)
Body Mass Index, mean (SD) 1112 25.7 (4.0) 26.0 (4.2) 0.166
Body Mass Index (kg/m2) 0.492
Desirable< 23 317 162 (29.1) 155 (27.9)
Overweight 23–27.5 473 242 (43.5) 231 (41.6)
Obese> 27.5 322 152 (27.3) 170 (30.6)
Education (years) < 0.001
< 10 years 167 66 (11.9) 101 (18.2)
10 - 12 years 497 278 (50.0) 219 (39.4)
> 12 years 448 212 (38.1) 236 (42.5)
C - reactive protein (mg/dl), mean (SD) 1112 6.1 (3.8) 3.5 (3.6) < 0.001
Inflammation < 0.001
Absent (CRP≤ 10 mg/dl) 999 472 (84.9) 527 (94.8)
Present (CRP> 10 mg/dl) 113 84 (15.1) 29 (5.2)
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consumption also showed a significant (p for trend
<0.01) dose–response relationship with systemic inflam-
mation (Figure 1).Table 2 Systemic inflammation and role of areca nut chewing
Univariate analysis
Odds ratio (95% CI) Wald Chi2
Age at screening (years)
Age 16-20 1
Age 21-25 0.83 (0.48 - 1.44) −0.66
Age 26-30 0.97 (0.53 - 1.78) −0.10
Age 31-35 1.01 (0.56 - 1.83) 0.03
BMI (kg/m2)
Desirable< 23 1
Overweight 23–27.5 0.90 (0.56 - 1.45) −0.41
Obese> 27.5 1.05 (0.63 - 1.74) 0.19
Education (years)
< 10 years 1
10 - 12 years 1.18 (0.65 - 2.16) 0.55
> 12 years 1.16 (0.63 - 2.14) 0.47
Group
Control 1
Areca nut chewers 3.23 (2.08 - 5.02) 5.23
Multivariate model included all the co-variates listed in the table.On interaction analysis, we did not find any significant
interaction (p-value for interaction 0.33) between BMI
and age of areca nut chewers in relation to systemic in-
flammation. However further age and BMI stratified, a comparison with healthy controls
Multivariate analysis
p value Odds ratio (95% CI) Wald Chi2 p value
1
0.51 0.79 (0.44 - 1.40) −0.81 0.42
0.92 0.89 (0.47 - 1.66) −0.37 0.71
0.98 0.99 (0.54 - 1.83) −0.02 0.99
1
0.68 0.91 (0.56 - 1.47) −0.38 0.71
0.85 1.11 (0.66 - 1.85) 0.39 0.7
1
0.58 0.94 (0.51 - 1.76) −0.18 0.86
0.64 1.07 (0.57 - 2.01) 0.22 0.83
1
< 0.001 3.30 (2.11 - 5.15) 5.26 < 0.001
Table 3 Systemic inflammation and areca nut chewing with tobacco additives, a comparison with raw areca nut
chewers
Univariate analysis Multivariate analysis
Odds ratio (95% CI) Wald chi2 p value Odds ratio (95% CI) Wald chi2 p value
Age at screening (years)
Age 16-20 1 1
Age 21-25 0.83 (0.48 - 1.44) −0.66 0.51 1.03 (0.51 - 2.11) 0.09 0.93
Age 26-30 0.97 (0.53 - 1.78) −0.10 0.92 1.13 (0.52 - 2.43) 0.30 0.76
Age 31-35 1.01 (0.56 - 1.83) 0.03 0.98 0.57 (0.26 - 1.24) −1.41 0.16
Age at screening (continuous) 0.98 (0.94 - 1.02) −1.14 0.25 0.97 (0.93 - 1.01) −1.28 0.20
BMI (kg/m2)
Desirable< 23 1 1
Overweight 23–27.5 0.90 (0.56 - 1.45) −0.41 0.68 0.80 (0.45 - 1.43) −0.75 0.46
Obese> 27.5 1.05 (0.63 - 1.74) 0.19 0.85 1.08 (0.59 - 1.98) 0.24 0.81
Education (years)
< 10 years 1 1
10 - 12 years 1.18 (0.65 - 2.16) 0.55 0.58 1.67 (0.73 - 3.82) 1.22 0.22
> 12 years 1.16 (0.63 - 2.14) 0.47 0.64 1.26 (0.55 - 2.87) 0.55 0.58
Group
Raw areca nut chewers 1 1
Areca with tobacco additives 1.70 (1.07 - 2.72) 2.24 0.03 1.98 (1.16 - 3.31) 2.61 0.009
Multivariate model included all the co-variates listed in the table.
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founding. On age-specific analysis, areca nut chewers
had significantly higher odds of having an elevated CRP
























Figure 1 The dose–response relationship between systemic inflamma
multivariate model adjusted for age, BMI and years of full time education.16–20 years (Figure 1). On BMI stratified analyses, all
areca nut chewers had significantly higher odds of hav-
ing an elevated CRP with highest effect in the obese
group (Figure 2).7-9 10-12 13-15
f packets/day
tion and areca nut chewing. Adjusted odds ratio calculated from a
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The findings of the present study indicate that areca nut
chewing is significantly associated with systemic inflam-
mation as measured by CRP. The results suggest that
areca nut chewing has a direct relationship with CRP in-
dependent of age, BMI and educational level. As
expected, the users of areca nut with tobacco additives
had even higher levels of CRP as compared to raw areca
nut chewers. Moreover, areca nut chewing has a signifi-
cant relationship with elevated CRP either measured as
a continuous or categorical variable.
The major constituents of areca nut are carbohydrates,
lipids, proteins, alkaloids and polyphenols[18]. There is
preliminary evidence from in vivo data, that areca nut
extracts augment the inflammatory response as well as the
expression of tumor necrosis factor-alpha in mice models
[19]. Extracts of both ripe areca nut and extracts of tender
areca nut significantly enhanced the production of tumor
necrosis factor-alpha and interleukin-1beta in peripheral
blood mononuclear cells in a dose-dependent and time-
dependent manner [20]. To the best of our knowledge,
our findings provide the first evidence which shows the
relationship of areca nut chewing and systemic inflamma-
tion measured by CRP in humans. The results of this
study are biologically plausible, as areca nut consumption
has been associated with the risk of developing diabetes























95% CI Odds ratio
Figure 2 Age and BMI specific risk of systemic inflammation among a
analysis, B=Age-specific analysis. Adjusted odds ratio calculated from a mu[8,11,13,21]. On the other hand, compelling evidence has
shown that inflammation is a primary aetiological factor
in development of hypertension [22,23], cardiovascular
diseases [24,25] and cancers [26,27]. Taken together, areca
nut might be increasing the risk of cardiovascular diseases
and cancers by augmenting the systemic inflammatory re-
sponse and elevating the levels of circulating inflammatory
markers. Regular high consumption of areca nuts for
longer duration may cause chronic inflammation, locally
in oral cavity and systemically, which could lead to mul-
tiple diseases.
Our results may have been influenced by the tobacco
components of areca nuts, but stratified analysis also
showed the higher odds of systemic inflammation among
raw areca nut chewers compared to healthy controls (data
not shown). The confounding effect of age and obesity on
systemic inflammation may have biased our results, al-
though, the positive (harmful) association of areca nut
chewing and systemic inflammation remained significant
after adjustments for age and BMI, we also stratified the
analysis based on age and BMI categories to remove the
residual confounding due to these factors. The overall
associations remain significant in stratified analysis except
among the younger age group (age 16–20 years). The null
association of areca nut chewing and systemic inflamma-
tion among younger participants could be explained by























16-20 21-25 26-30 31-35
Age in years
95% CI Odds ratio
reca nut chewers as compared to controls. A= BMI stratified
ltivariate model adjusted for age and years of full time education.
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more, younger individuals tend to be physically active
while participating in outdoor sports or leisure activities;
exercise and physical activity has an inverse relationship
with inflammation, reported by many studies [28,29]. So
the harmful effect of areca nut chewing may actually be
attenuated by some other unknown lifestyle factors result-
ing in a null finding in the younger age group, which we
have reported.
The major strength of this cross sectional study was
that it was population-based and we had a fairly large
sample to examine associations between areca nut chew-
ing and systemic inflammation. Although, our findings
suggest that areca nut chewing has a strong relationship
with systemic inflammation and hence may have a role
in the development of systemic diseases at a later stage
but causality can not be established in a cross-sectional
study. The contribution of areca nut chewing in devel-
opment of chronic diseases, should, therefore be
assessed by larger prospective studies in relation to sys-
temic inflammation.
This study has several limitations which need to be
mentioned. As the participants were selected from one
region of this city, so given the sample limitations one
can not draw conclusions about the population level
estimates from this study. We used only male indivi-
duals; therefore, it is difficult to assume that the preva-
lence of systemic inflammation would also be similar
among the female population in this country. Indeed it
may be even higher compared to males, as an earlier
study from Taiwan suggested that the risk of hyperten-
sion was significantly higher among female areca nut
chewers as compared to males [10]. Most of the indivi-
duals included in our study were from average or below
average socio-economic class, so the results are not gen-
eralisable to all the social classes of this country.Public health implications
Areca nut use poses significant and avoidable morbidity
and mortality. The present finding suggests a possible
mechanism by which areca nut chewing is related with
chronic diseases. Confirmation of causality between
areca nut use and systemic inflammation and then fur-
ther development of chronic disease would enhance the
significance of primary prevention programs. Health
education and awareness are perhaps the most crucial
interventions required to be delivered so that the ad-
verse effects of the substance can be appreciated by the
community. Addressing a culturally sanctioned sub-
stance in terms of addiction and harm may meet with
considerable resistance, especially if attention resulted
in compromised supply or increased cost [30]. These
interventions need to be focused on all age groups,particularly in early age school children to avoid future
morbidity and mortality associated with this substance.
Conclusions
Areca nut chewing was significantly associated with sys-
temic inflammation. Systemic inflammation was signifi-
cantly higher among men using areca nuts with tobacco
additives. Further evidence is required to confirm the
findings and its relationship with development of cardio-
vascular diseases and cancers.
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